Her2 DNA vaccine as adjunct treatment for cancers in companion animals
US9040053B2 · kind B2 · utility
0Cited by
2References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 13, 2011 |
| Grant date | May 26, 2015 |
| Priority date | — |
| Expiry date | Oct 13, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The application discloses therapeutic vaccines based upon the “pING” DNA plasmid vector expressing the gene encoding the rat Her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the Her2 antigen, and prolong the post-surgical disease free interval and/or survival time. Also included are therapeutically effective methods of immunization using said vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.